Odonate Therapeutics, Inc.
Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapies that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, oral therapy belonging to the taxane class. Odonate recently initiated CONTESSA, a multinational randomized Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer. Odonate’s goal is to develop tesetaxel as an effective chemotherapy choice that provides quality-of-life advantages over current alternatives. www.odonate.com